
|Articles|March 3, 2008
Post-marketing liver injury reports lead to Tysabri PI update
Liver injury warnings added to natalizumab prescribing information.
Advertisement
Reports of markedly elevated serum hepatic enzymes and elevated total bilirubin in patients receiving natalizumab (
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
Vaccine Policy in Flux: Stories Pharmacists Need to Follow
3
Pharmacists Want Prescribing Authority With Proper Training, Support
4
Q&A: Pharmacists Help Patients Navigate Pneumococcal Vaccine Options
5






























